RGEN
T2Repligen Corporation
OverviewRepligen Corporation develops and sells advanced bioprocessing technologies and integrated systems for biological drug production. Their portfolio includes prod
Repligen Corporation develops and sells advanced bioprocessing technologies and integrated systems for biological drug production. Their portfolio includes products for purifying biologics (chromatography), cell separation (filtration), and real-time process analysis (analytics), alongside specialized proteins. They serve biopharmaceutical companies, research laboratories, and contract manufacturing organizations worldwide, recently seeing significant growth in Asia Pacific, particularly China.
- What They Do (Plain English & Analogies)
- Repligen Corporation makes specialized tools and systems that are essential for creating biological medicines, like vaccines and advanced therapies. Think of them as providing the high-tech kitchen equipment and ingredients for a pharmaceutical chef. They offer products for different stages of drug production: from growing the cells that make the medicine (like a fermentation tank), to purifying the medicine (like a super-fine filter or a specialized sieve), and even analyzing the medicine to ensure quality (like a precise measuring device). Their technologies help pharmaceutical companies and contract manufacturers produce these complex drugs more efficiently and effectively, serving customers globally across North America, Europe, and Asia.
- Very Brief History
- Founded in 1981 and headquartered in Waltham, Massachusetts, Repligen Corporation has evolved to specialize in advanced bioprocessing technologies. Over the years, the company has strategically expanded its portfolio through both organic development and acquisitions, focusing on critical components for biological drug production. A recent key development in 2026 included the divestment of its non-core Polymem operation in France and the establishment of a new OEM partnership in China to enhance local manufacturing capabilities.
- "Street Stereotype"
- Repligen is generally perceived by investors and analysts as a high-growth pure-play company focused on downstream bioprocessing filtration and chromatography. It is seen as offering highly sensitive operating leverage directly tied to the early stages of a biotech funding recovery and an increase in clinical manufacturing.
- Subsidiaries On Linked In*
- {"subsidiaries":[]}
- Customer Sectors & Example Clients
- Repligen serves a broad range of customers in the life sciences industry. Their customer sectors include biopharmaceutical companies, diagnostics companies, laboratory researchers, and contract manufacturing organizations (CDMOs). They also cater to emerging biotechs and large pharma companies. While specific client names are not provided in the transcript, based on their business model and industry, their clients would typically include major global pharmaceutical companies, leading contract development and manufacturing organizations (CDMOs) like Lonza or Fujifilm Diosynth Biotechnologies, and innovative biotech startups focused on developing new biological drugs.
- New Customers / Segments They'Re Targeting
- Repligen is actively targeting and seeing significant growth from emerging biotechs, which saw over 20% growth in Q1 2026. They are also focusing on expanding their presence and competitiveness in the China market through a new OEM partnership, aiming to increase access to local manufacturing starting in 2027. Furthermore, they are investing in IT modernization and AI implementation across all functions, and their analytics franchise is well-positioned for an increasingly digital environment, suggesting a focus on customers seeking advanced digital and data-driven solutions.
- Supply Chain And Sourcing Geographies
- Repligen's supply chain involves manufacturing and sourcing in various geographies. The company recently divested its Polymem operation in France, which was a manufacturing facility. They are establishing a new OEM partnership in China to expand capabilities and local manufacturing, which is expected to begin in 2027. This indicates a strategic move towards localized sourcing and manufacturing in key growth regions like China. The company also mentions optimizing its manufacturing footprint for increased cost efficiency as part of its transformation office initiatives.
- Sales Geographies And Expansion Plans
- Repligen currently sells its products across North America, Europe (EMEA), and the Asia Pacific region, including China. In Q1 2026, North America represented approximately 46% of total revenue, EMEA 37%, and Asia Pacific and the rest of the world approximately 17%. Asia Pacific was the fastest-growing region, with China experiencing a near doubling of revenues. The company has explicit plans to expand its presence and capabilities in China through a new OEM partnership, which will increase local manufacturing and competitiveness in the region starting in 2027. They view Asia Pacific as a key strategic region and are committed to expanding their collaboration with partners in China.
- How Key Themes May Help/Hurt
- Repligen is well-positioned to benefit significantly from the 'MedTech Long '26: Life Science Tools & Bioprocessing' theme. The robust demand for biologics and GLP-1 therapeutics will drive increased need for their specialized bioprocessing consumables and filtration systems. The biotech funding recovery is a direct tailwind, as increased R&D spending by early-stage biotechs translates into demand for Repligen's analytical instruments and other tools, as evidenced by the 20%+ growth from emerging biotechs. Pharma reshoring and CDMO outsourcing for supply chain resilience will also boost demand for bioprocessing equipment and services, benefiting Repligen's offerings. The company's focus on margin expansion and operational efficiency through its transformation office aligns with the theme's emphasis on strong execution. However, persistent geopolitical tensions and potential China market weakness could pose challenges, although Repligen's new OEM partnership in China aims to mitigate some of these risks by localizing operations.
3 Main Long-Term Bull Details
- Differentiated Product Portfolio and Innovation Leadership: Repligen possesses a highly differentiated product portfolio, particularly in process analytics and ATF technology, where they are investing heavily in R&D for new product launches and advancements. This innovation leadership positions them to outpace the market and drive robust growth in critical bioprocessing areas.
- Strong Leverage to Biotech Funding Recovery and Emerging Biotechs: The company is a direct beneficiary of the recovering biotech funding environment, with emerging biotechs showing consistent strong growth. As this funding translates into increased R&D and clinical manufacturing, Repligen's tools and services will see sustained demand, especially given their relatively high exposure to this segment.
- Strategic Expansion in Key Growth Geographies and Operational Efficiency: Repligen's strategic focus on high-growth regions like Asia Pacific, particularly China, through local partnerships and manufacturing, positions them to capture significant market share. Coupled with the 'transformation office' initiatives aimed at optimizing manufacturing, improving profitability, and leveraging AI, the company is set for accelerated margin expansion and scalable growth.
3 Main Long-Term Bear Details
- Customer Decision-Making and Capital Equipment Tap: While order trends are solid, the company notes that faster customer decision-making is needed, especially for capital equipment. A prolonged delay in capital equipment spending by biopharma companies could temper growth, as these larger projects are subject to customer site preparedness and broader market confidence.
- Gene Therapy Headwinds and Customer-Specific Inventory Management: Repligen has experienced headwinds in gene therapy and temporary inventory management by specific customers impacting ATF sales. While these are considered transitory, a longer or more widespread impact from such dynamics could affect growth in certain product franchises.
- Intensifying Competition and Market Dynamics in China: Despite strategic partnerships, the China market is becoming increasingly competitive. While Repligen aims to differentiate through localization, a failure to effectively navigate this competitive landscape or unforeseen challenges with local partnerships could hinder their growth ambitions in this critical region.
- Competitors And Differentiation
- Repligen operates in a competitive landscape, particularly noting increased competition in the China market. While specific competitors are not named in the transcript, in the bioprocessing tools and systems market, they would compete with companies like Danaher (through Cytiva), Sartorius Stedim Biotech, and Thermo Fisher Scientific. Repligen differentiates itself through its 'differentiated product portfolio' and 'process intensification leadership position,' particularly with its ATF technology. They focus on innovation, with significant R&D investment in new process analytics technologies and advancements in ATF. Their strategy in China involves capitalizing on local companies through OEM partnerships to gain market share and appear more 'Chinese' to defeat local competition.
- Recent Performance & What The Market'S Focused On
- Repligen delivered a strong start to 2026, reporting $194 million in Q1 revenue, representing 15% reported growth and 11% organic growth, coupled with 160 basis points of adjusted operating margin expansion. The company raised its adjusted earnings per share guidance for the full year to $1.97 to $2.05, while reiterating organic revenue growth guidance of 9% to 13%, despite a $7 million reduction in reported revenue outlook due to the Polymem divestment. The market is focused on the continued recovery of emerging biotech funding, the impact of the new OEM partnership in China, the progress of the 'transformation office' in driving margin expansion, and the anticipated rebound of ATF growth in 2027 after temporary customer inventory management.
- Revenue Segments And Estimated Mix
- North America — Mix: ~46%; Source: Q1 2026 transcript; Trend: Mid-single digit growth
- EMEA — Mix: 37%; Source: Q1 2026 transcript; Trend: More than 20% growth
- Asia Pacific and Rest of World — Mix: ~17%; Source: Q1 2026 transcript; Trend: More than 25% growth, with China nearly doubling
- Filtration (Product Franchise) — Mix: n/m; Source: Q1 2026 transcript; Trend: Mid-single digit reported growth in Q1, mid-single digit outlook for 2026
- Chromatography (Product Franchise) — Mix: n/m; Source: Q1 2026 transcript; Trend: Over 25% growth in Q1, 20%+ outlook for 2026, expected slightly higher mix
- Proteins (Product Franchise) — Mix: n/m; Source: Q1 2026 transcript; Trend: Mid-teens growth in Q1, at least low double digits outlook for 2026
- Analytics (Product Franchise) — Mix: n/m; Source: Q1 2026 transcript; Trend: Over 50% growth in Q1, 20%+ outlook for 2026
- Consumables (overall) — Mix: n/m; Source: Q1 2026 transcript; Trend: Double-digit growth in Q1
- Capital Equipment (overall) — Mix: n/m; Source: Q1 2026 transcript; Trend: Solid growth in Q1
- Services — Mix: n/m; Source: Q1 2026 transcript; Trend: Over 30% growth in Q1
- Product Brands
- OPUS
- CaptivA
- XCell
- TangenX
- KrosFlo
- Spectra/Por
- SpectraFlo
- ProConnex
- SoloVPE
- FlowVPE
- FlowVPX
- SoloVPE PLUS
Bull / Bear DetailsRepligen, a high-growth pure-play in bioprocessing, is well-positioned for a sustained rebound in biotech funding and clinical manufacturing, evidenced by stron
Thesis
Repligen, a high-growth pure-play in bioprocessing, is well-positioned for a sustained rebound in biotech funding and clinical manufacturing, evidenced by strong Q1 2026 performance across its portfolio, particularly in Analytics and Chromatography. Strategic initiatives like the transformation office and a new China OEM partnership are set to drive margin expansion and market penetration, reinforcing its operating leverage. Updated 2026-07-21.
Bull case
Repligen is a direct beneficiary of the biotech funding recovery, with emerging biotech revenues growing over 20% for four consecutive quarters. This positive trend, coupled with significant increases in overall biotech funding in Q1 and April 2026, is translating into a robust capital equipment funnel and increased R&D spending, signaling strong future demand for Repligen's bioprocessing solutions.
The company's newly established transformation office is a key driver for margin expansion, aiming to achieve at least one point of annualized margin benefit by the end of 2027 and accelerating the path to a 30% adjusted EBITDA margin by 2030. This initiative, alongside the strategic divestiture of the low-margin Polymem business, underscores a strong commitment to operational efficiency and profitability.
Repligen is demonstrating strong strategic growth in critical geographies and product segments. Asia Pacific, led by a near doubling of revenues in China in Q1 2026, is a significant growth engine, bolstered by a new OEM partnership for local manufacturing. High-growth franchises like Analytics (50%+ growth), Chromatography (25%+ growth), and Proteins (mid-teens growth) further solidify its market position.
Bear case
Despite improving biotech funding and a strong opportunity funnel, the conversion of capital equipment orders into recognized revenue remains subject to slower customer decision-making and varying levels of customer site preparedness, particularly for larger projects and onshoring initiatives. This can introduce delays in revenue realization and impact short-term growth projections.
The company faces product-specific headwinds, notably a moderated outlook for its ATF consumables in 2026 due to temporary customer inventory management issues. While management anticipates this will become a tailwind in 2027, the near-term impact on a key filtration segment creates uncertainty and could temper overall growth for the current year.
Persistent geopolitical tensions and increasing competition, especially in the strategically important China market, pose ongoing risks. Repligen acknowledges facing more local competition in China and anticipates tariff surcharges in 2026, which could pressure margins and market share despite efforts to localize operations through partnerships.
Bull / Bear Case
- Bear Case
- Despite improving biotech funding, the conversion of capital equipment orders into recognized revenue remains subject to slower customer decision-making and varying levels of customer site preparedness, particularly for larger projects and onshoring initiatives, introducing delays in revenue realization and impacting short-term growth projections. The company faces product-specific headwinds, notably a moderated outlook for its ATF consumables in 2026 due to temporary customer inventory management issues. While management anticipates this will become a tailwind in 2027, the near-term impact on a key filtration segment creates uncertainty. Persistent geopolitical tensions and increasing competition, especially in the strategically important China market, pose ongoing risks, with Repligen acknowledging more local competition and anticipating tariff surcharges in 2026, which could pressure margins and market share.
- Bull Case
- Repligen is a direct beneficiary of the biotech funding recovery, with emerging biotech revenues growing over 20% for four consecutive quarters, signaling strong future demand for its bioprocessing solutions. The company's newly established transformation office is a key driver for margin expansion, aiming for at least one point of annualized margin benefit by the end of 2027 and accelerating the path to a 30% adjusted EBITDA margin by 2030, supported by the strategic divestiture of the low-margin Polymem business. Repligen is demonstrating strong strategic growth in critical geographies and product segments, particularly Asia Pacific, with a near doubling of revenues in China in Q1 2026, bolstered by a new OEM partnership for local manufacturing. High-growth franchises like Analytics (50%+ growth), Chromatography (25%+ growth), and Proteins (mid-teens growth) further solidify its market position and innovation leadership.
- More Compelling & Why
- Bear. Repligen's current valuation, with a forward P/S ratio of approximately 9x, appears stretched given the near-term uncertainties. The strongest argument for the bear case is the persistent challenge of converting a robust capital equipment funnel into recognized revenue due to slower customer decision-making and varying site preparedness, which can delay growth. My view would flip to bullish if the company demonstrates a clear acceleration in capital equipment order conversion and provides concrete evidence of the ATF tailwind materializing earlier or stronger than anticipated, alongside a more attractive valuation.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| Transformation Office Progress & Margin Expansion | The newly formed transformation office is critical for accelerating Repligen's path to 30% adjusted EBITDA margin by 2030, driving operational efficiencies and directly impacting future profitability and earnings per share. | Monitor for updates on specific initiatives (manufacturing footprint optimization, product line profitability, IT modernization, AI implementation) and any early indications of the 'at least one point of annualized margin benefit' before the end of 2027. | Bullish if management reports specific project milestones achieved ahead of schedule, or if the projected annualized margin benefit by the end of 2027 is revised upwards. Bearish if non-recurring charges exceed the $5M-$6M estimate or benefits are delayed. | Repligen's quarterly earnings calls (e.g., Q2 2026 call on July 28, 2026), press releases, and Form 10-Q/K filings. | Industry news on bioprocessing operational efficiency and AI implementation in manufacturing. Google Trends for "Repligen AI" or "Repligen efficiency". | Thinknum: Repligen job postings for "transformation," "process improvement," or "AI/ML engineer" roles (growth/volume). |
| ATF Consumables Demand Recovery & 2027 Outlook | Alternating Tangential Flow (ATF) is a core technology for Repligen. While facing a temporary inventory management headwind in 2026, its confirmed recovery and strong growth in 2027 are crucial for the filtration franchise's performance and overall revenue. | Observe management commentary on customer inventory levels and any signs of earlier-than-expected demand recovery for ATF consumables. Pay close attention to specific guidance for ATF growth in 2027 during future earnings calls. | Bullish if management indicates an earlier resolution of customer inventory management issues than anticipated, leading to a stronger 2027 outlook for ATF. Bearish if the 2026 moderation extends or the 2027 tailwind is less robust than expected. | Repligen's quarterly earnings calls (e.g., Q2 2026 call on July 28, 2026) and investor presentations. | Industry reports on perfusion and cell culture processing trends, Repligen's own technical publications on ATF. | Expert network calls with bioprocessing customers regarding inventory levels and technology adoption. |
| Emerging Biotech Spending & Funding Flow-Through | Emerging biotechs are a significant growth driver for Repligen, and sustained recovery in biotech funding directly translates to increased R&D spending and demand for the company's life science tools and services. | Monitor for continued 20%+ growth in emerging biotech revenue in Q2 2026 and beyond. Track global biotech venture capital funding data for Q2 2026, which showed a strong rebound. | Bullish if emerging biotech revenue growth remains above 20% in Q2 2026 and subsequent quarters, or if global biotech venture capital funding for Q2 2026 shows sustained strong year-over-year growth (e.g., doubling last year's Q2). Bearish if growth moderates significantly or funding declines. | Repligen's quarterly earnings calls (e.g., Q2 2026 call on July 28, 2026), PitchBook-NVCA Venture Monitor (Q2 2026 data released in July/August). | Crunchbase: Biotech funding rounds announcements. SynBioBeta: Quarterly biotech funding reports. | PitchBook: Global Biotech Venture Capital Funding (USD Billions). |
| China OEM Partnership Operationalization & Expansion | The critical OEM partnership signed in China is vital for enhancing Repligen's competitiveness and market access in the rapidly growing Asia Pacific biopharma region, providing a significant long-term growth runway. | Look for announcements regarding the commencement of local manufacturing operations in China (expected beginning of 2027), and any updates on expanding the multiphase, multiproduct arrangement or forming additional partnerships. | Bullish if the OEM partner begins operations earlier than expected (e.g., late 2026) or if Repligen announces an expansion of the partnership's scope or new partnerships in China ahead of schedule. Bearish if operationalization is delayed. | Repligen's press releases, quarterly earnings calls (e.g., Q2 2026 call on July 28, 2026), and industry news in the Asia Pacific region. | Local Chinese biopharma news outlets (translated), government announcements on local manufacturing initiatives. | S&P Global Market Intelligence: News sentiment analysis for "Repligen China partnership." |
| Capital Equipment Order Intake & Funnel Conversion | Strong capital equipment orders and conversion of Repligen's 'robust capital equipment funnel' are leading indicators of customer spending, signaling a healthy demand environment and future revenue growth, particularly if the 'capital equipment tap will open.' | Observe commentary on order trends in Q2 2026 and subsequent quarters, focusing on Analytics and mixers. Look for specific mentions of RFP wins translating into delivered orders and faster conversion of the 'high probability opportunity funnel.' | Bullish if order intake continues to accelerate beyond the Q1 March pickup, or if management indicates a quicker conversion of the high-probability funnel into recognized revenue. Bearish if order intake slows or funnel conversion remains sluggish. | Repligen's quarterly earnings calls (e.g., Q2 2026 call on July 28, 2026) and investor presentations. | Industry news on bioprocessing capital expenditure trends, competitor earnings calls for similar equipment. | Bloomberg Terminal: Bioprocessing equipment order growth for key players (e.g., TMO, DHR, DIM.PA). |
Key Reported Metrics, Reratings Triggers & ResultsAnalytics is a high-growth segment for Repligen, leading performance in the last quarter. Continued strong growth in this area signals successful product innova
No data for this section.
Key QuestionsWill the acceleration in capital equipment orders, particularly from RFP wins and the 'tap opening,' translate into stronger recognized revenue and improved gui
Will the acceleration in capital equipment orders, particularly from RFP wins and the 'tap opening,' translate into stronger recognized revenue and improved guidance for Repligen in the upcoming quarters?
- Question 2
Can Repligen sustain the strong 20%+ growth from emerging biotechs, and will the recent rebound in biotech funding translate into a more significant and sustained increase in customer spending in the next quarter?
- Question 3
Will Repligen's newly launched transformation office demonstrate tangible progress on its initiatives (e.g., manufacturing optimization, product profitability) in the next quarter, providing confidence in achieving the targeted margin expansion by 2027?
Earnings Transcript Summary
· 2026Q1 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 1. Margin Expansion and Operational Efficiency: Management is committed to expanding margins and achieving a 30% adjusted EBITDA margin by 2030, accelerated by the newly formed transformation office. This office will focus on optimizing manufacturing footprint, improving product line profitability, enhancing customer service, and accelerating IT modernization and AI implementation. 2. Growth in Asia, particularly China: Repligen is highly focused on its growth opportunity in Asia, especially China, where they saw near-doubling of revenues in Q1 2026. They recently signed a critical OEM partnership in China to expand capabilities and local presence, aiming to increase competitiveness and access to local manufacturing starting in 2027. 3. IT Investments and Digitization/AI: The company is investing in its IT organization, making key additions to the team (data management and AI experts), and implementing AI across various functions (legal, commercial, supply chain). They are also optimizing data infrastructure to better implement AI and leveraging their analytics franchise for a digital environment. | The overall takeaway of the call is positive and confident. Repligen delivered strong Q1 2026 results, with 15% reported revenue growth and 11% organic growth, outperforming expectations on margins. Management is optimistic about the full-year outlook, reiterating organic growth guidance and raising EPS guidance due to strong Q1 performance and the divestiture of the Polymem business. Key strategic initiatives, such as the transformation office for margin expansion, the new OEM partnership in China for regional growth, and continued IT/AI investments, are progressing well. While acknowledging some temporary headwinds (gene therapy, ATF inventory management), management expressed strong conviction in their differentiated product portfolio, global team, and strategy for robust future growth, especially in Analytics and Proteins. The tone was upbeat, emphasizing execution, strategic progress, and confidence in future performance. | Q4 2025 Organic Revenue Growth: 14%. Analytics: Strong performance (specific percentage not provided). Proteins: Strong performance (specific percentage not provided). Specific year-over-year growth rates for Filtration, Chromatography, Services, North America, EMEA, Asia Pacific, CDMO, Biopharma, and Emerging Biotechs for Q4 2025 were not explicitly provided in the search results. | 1. Q1 Operating Margins and Transformation Office Impact: Analysts questioned the drivers of the strong Q1 operating margins (incidental vs. reprioritization) and the financial impact and timing of the transformation office. Management Response: Q1 gross margin was driven by volume leverage, pricing, and favorable product mix (Analytics, accretive filtration products), with some cost absorption timing that will normalize. The transformation office is a structured program for "fit for growth" and margin expansion, expected to generate at least one point of annualized margin benefit by the end of 2027 (run rate), on top of the normal run rate, accelerating the path to 30% EBITDA by 2030. 2. Capital Equipment Demand and RFP Wins: Analysts inquired about the pickup in capital equipment orders in March, where the strength was most notable (category/customer type), and the status of RFPs they were awaiting. Management Response: Capital equipment increased year-on-year in Q1 (easy comp), driven by Analytics and mixers, with a nice pickup in China. Orders increased significantly in the second half of Q1, particularly in March, including conversion of the capital equipment funnel. They are starting to win some of the RFPs answered late last year, which is very encouraging. 3. Emerging Biotech Recovery and Funding Impact: Analysts asked about what is needed for emerging biotech to return to full strength, given the 20%+ growth for the fourth consecutive quarter, and the potential timing and contribution of the biotech funding recovery. Management Response: Management is very happy with the significant growth from emerging biotech (above 20% in Q1), noting that Q1 comps were easy and activity levels are still slightly below historical levels. They expect the improved biotech funding environment (Q1 funding almost double last year, strong April) to become a stronger tailwind from Q2/Q3 onwards. Emerging biotech currently represents 8-9% of total sales, trending back to the historical 10%. | Reported Revenue Growth: 15%; Organic Revenue Growth: 11%; Analytics: 50%+ growth; Consumables (including protein): double-digit growth; Services: 30%+ growth; Filtration: mid-single digits growth; Chromatography: over 25% growth; Proteins: mid-teens growth; North America: mid-single digits growth; EMEA: more than 20% growth; Asia Pacific: more than 25% growth (with China nearly doubling revenues); CDMO revenues: mid-teens growth; Biopharma revenues: grew; Emerging biotechs: 20%+ growth; OEM and integrated demand: very robust growth. |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| Repligen is expanding its eligible market through a new OEM partnership in China, which will increase competitiveness and access to local manufacturing starting in 2027. The company is also looking at expanding this collaboration and potentially with other partners in China over the next several years. Growth in Asia Pacific, particularly a near doubling of revenues in China, highlights this expansion. Additionally, new modalities like cell therapy, and gene therapy (excluding a specific headwind), are contributing to growth. The Analytics franchise is well-positioned for an increasingly digital environment with its PAT product portfolio for both upstream and downstream data, including the integration of FlowVPX into filtration systems and a partnership with Novasign for digital twin capabilities. ATF technology is being designed into multiple new products and modalities, and OPUS columns are winning new customers globally. | Repligen acknowledges facing much more competition, especially in China, and is implementing a strategy to capitalize on local companies to regain market share, emphasizing the need to appear 'much more really Chinese' to defeat local competition. The company expresses high confidence in its ATF technology leadership, with zero doubt about leading process intensification for the next several years due to ongoing innovation and planned product launches. | The broader industry is showing encouraging signs, with Repligen remaining convinced that the 'capital equipment tap will open.' CDMO revenues grew mid-teens, and biopharma revenues increased despite difficult comparisons. Emerging biotechs saw over 20% growth, though demand remains below historical levels. Biotech funding is showing a strong rebound, with Q1 funding almost double last year and April seeing approximately $10 billion in funding. Digitization is identified as a multiyear journey and a key strategic focus. Onshoring projects are also impacting customer preparedness and lead times for equipment delivery. | Repligen is reiterating its full-year 2026 organic growth guidance of 9% to 13% and has increased its adjusted earnings per share guidance. The company expects 110 to 160 basis points of gross margin expansion and 160 to 200 basis points of operating margin expansion for the year. The transformation office is expected to accelerate the path to a 30% adjusted EBITDA margin by 2030, delivering at least one point of annualized margin benefit by the end of 2027, with full benefits in 2028. China is anticipated to be a meaningful player in biopharma for years to come. Q2 organic revenue growth is expected to be similar to Q1, with solid operating margin expansion, though Q3 is projected to be the lowest margin quarter. ATF is expected to return to strong growth in 2027 and beyond, while chromatography is forecast for over 20% growth and proteins for at least low double-digit growth in 2026. | Life | AI implementation across various business functions (legal, commercial, supply chain, IT modernization), digitization journey, digital twin capabilities, and the impact of onshoring projects on customer site preparedness and equipment delivery timelines. | Great execution once again by our team enabled us to deliver 15% reported revenue growth or 11% organic and 160 basis points of adjusted operating margin expansion. We did see encouraging signs in the first quarter, and remain convinced that capital equipment tap will open. Analytics led the way with 50% plus growth, but all of our franchises grew nicely again in the first quarter. We are reiterating our expectation for 9% to 13% organic growth, while updating our reported revenue guidance to reflect the sale of our noncore and low-margin Polymem business. This reduces our full year revenue outlook by $7 million, but improved our margin outlook. This included a near doubling of revenues in China with our best revenue quarter in the country in over 2 years. After our trip, we have more conviction than ever that China will be a meaningful player in biopharma for years to come. I'm absolutely very bullish about that market for the next several years. I think the best is still to come here for sure. | As expected, new modalities were dilutive to growth given the gene therapy headwind we previously discussed. This also contemplates a moderated ATF outlook in 2026 due to customer-specific timing dynamics that are expected to be a tailwind in 2027. Our guidance also assumes a couple of million dollars tariff surcharges in 2026. The third quarter will likely represent the lowest margin quarter of the year. What we're not still controlling fully is decision-making. What we don't control fully is customer preparedness and especially with ensuring that, that's something we're all going to have to figuring out better in the upcoming few quarters here. | Repligen has made key additions to its team this year, including new data management and AI experts. The company is actively building a great team and gaining traction with key customers in Asia, attributing strong performance in China to the team put in place. |